Cohance Lifesciences Ltd · NSE:COHANCE

Cohance Lifesciences — Suven Pharmaceuticals — Investor Presentation (2020)

40 slides from Cohance Lifesciences's investor presentation, 2020

  1. Slide 1: Suven Pharmaceuticals Limited

    SUVEN PHARMACEUTICALS LIMITED Partnering Drug Development, Manufacturing ……and beyond! 1

  2. Slide 2: Vision

    Vision To Emerge as a leading player by providing full spectrum services in drug development, manufacturing and support services under collaboration with leading global life science players. 2

  3. Slide 3: Business Structure

    Business Structure • In operation since 1989 to 2003 as SUVEN PHARMACEUTICAL LTD. • Profitable for the last decade • Transformed to SUVEN LIFE SCIENCES LTD from 2003 to 2019. • Demerged from Suven Life Sciences and in operation as Suven Pharmaceuticals Limited since January, 2020. • Strong asset bas

  4. Slide 4: 30 years of Pharmaceutical Relationship

    30 years of Pharmaceutical Relationship • Pharmaceutical product development • Product scale up and manufacturing services Formulations • Pharmaceutical Analytical services • Regulatory management services Relationship with more than 22 global pharmaceutical companies 4

  5. Slide 5: Strategic Business Segments

    Strategic Business Segments • Formulation Development and Manufacturing Centre (FDC) Full spectrum services in Drug Development and Manufacturing 5

  6. Slide 6: Facility Capacities Overview

    Facility Capacities Overview - 110,000+ sq. ft of World-class Infrastructure comprising • cGMP Scale-up • Manufacturing and Packing of Exhibit, Commercial and Clinical Supply Batches • Warehouse • Analytical Method Development & Validation Laboratories • Dissolution Testing Laboratory • Wet Chemistr

  7. Slide 7: @ Suven

    @ SUVEN

  8. Slide 8: FDC Services

    FDC Services Formulation Development Centre -a Natural extension to the existing CRAMS Business Manufacturing Solid Oral dosage forms Liquid Oral dosage forms Topical dosage forms Analytical Development Method development Method Validations Impurity Profiling RS Estimation Microbiology Stability Man

  9. Slide 9: Manufacturing Support

    Manufacturing Support Dosage Forms • Solid • Liquid • Topical Support • Scale up Batches • Exhibit Batches • Validation & Commercial Batches • Clinical Supplies • BE/BA Supplies 9

  10. Slide 10: Solid Dosages

    Solid Dosages • Tablets: Immediate Release, Sustained Release, Delayed Release, Chewable and Orally Dissolving. • Capsules: Powders, Multi-particulates and Tablets in Capsules. • Powders: Immediate Release, Sustained Release, Delayed Release, Powders for Sachet or Suspension & Taste Masking. • Multi

  11. Slide 11: Process Capabilities - Solids

    Process Capabilities - Solids • Blending • Controlled Release • Sizing/Milling • Solubility Enhancement • High Shear and Fluid Bed • High and Low Dose Potency Granulation (aqueous or organic • Taste-Masking solvents) • Orally Disintegrating and • Tableting Chewable Tablets • Encapsulation • Packagin

  12. Slide 12: Manufacturing Equipment List

    Manufacturing Equipment List S. No Description Capacity Solid Dosage Form Module 1 Multi Mill 25-300 kg/hr 2 Vibro Mechanical sifter 600 mm Dia 3 Rapid Mixer Granulator 75 & 150 L 4 Fluid Bed Processor 35 & 125 L 5 Double Cone Blender 50, 100 & 200 L 6 Octagonal Blenders 100, 250 & 1000 L 7 Roller C

  13. Slide 13: Manufacturing Equipment List

    Manufacturing Equipment List S. No Description Capacity 19 Empty Capsule Sorter Up to 2,00,000 Capsule/Hr 20 Dedusting and Polishing Machine Up to 1,00,000 Capsule/Hr 25000 Cap/Hr (0.5 million 21 Auotmatic Capsule Filling Machine (AF25T) capsules/ day) 23 Dedusting and Polishing Machine Up to 1,00,0

  14. Slide 14: Process Capabilities - Liquids

    Process Capabilities - Liquids • Topical liquids: Rx, OTC, and Personal care products for topical administration. • Oral solutions. • Oral suspensions: Immediate Release and Powders for Suspension. 14

  15. Slide 15: Manufacturing Equipment List

    Manufacturing Equipment List S. No Description Capacity Liquid Dosage Form Module 1 Premixing Tank 60L, 1000 L 2 Mixing Tank 75L, 2000 L 3 Holding Tank 2000 L 4 Filtration Unit 0.2 Micron, 0.45 Micron 5 Bottle Cleaning M/C 50 - 80 bottles/min (30 ml - 500 mL) 6 Caps Cleaning M/C 80 caps/min 7 Bottle

  16. Slide 16: Liquid Oral Facility

    LIQUID ORAL FACILITY 16 Premixing Tank 1000L 2000L Mixing Tank and 2000L Holding Tank

  17. Slide 17: Analytical Services / Stability

    @ SUVEN Analytical Services/ Siability

  18. Slide 18: Analytical Method Development, Validation and Testing

    Analytical Method Development, Validation and Testing • Our fully equipped GLP Analytical Laboratory is well suited for Drug Product Analytical Method Development, Validation and Analysis to support R&D, Exhibit, Clinical, Validation and Commercial activities. • Our Microbiology Lab is equipped to c

  19. Slide 19: Method Development and Validations

    Method Development and Validations • Assay • Related Substances • Chiral Purity • Elemental Impurities • Extractable and Leachable Study Dissolution • USP Apparatus I • USP Apparatus II • USP Apparatus III Cleaning Verification • Compound Specific Method • Total Organic Carbon (TOC) 19

  20. Slide 20: Analytical Services Microbiology Laboratory Instruments

    ANALYTICAL SERVICES MICROBIOLOGY LABORATORY INSTRUMENTS • Horizontal Laminar Air Flow Benches (2 No's) • Incubators (2000 liters) • Cooling Incubator 2-8 °C (400 liters) • Autoclave • Colony Counter • Carl Zeisis Microscope 20

  21. Slide 21: Analytical Services Infrastructure

    ANALYTICAL SERVICES INFRASTRUCTURE • Walk-in Stability Chambers of 2,20,000 liters Capacity (10 numbers) • Centralized data acquisition for monitoring and trending Temperature and Humidity 24/7. • Stability Studies meeting the ICH Guidelines and any customer specific requirements. 21

  22. Slide 22: ICH Stability Storage and Testing

    ICH Stability Storage and Testing • 40±2°C / 75±5% RH • 30±2°C / 65±5% RH • 30±2°C / 75±5% RH • 25±2°C / 60±5% RH • 5±3°C (2-8°C) • Photo Stability • Flexible Conditions 22

  23. Slide 23: Analytical Instrumentation

    Analytical Instrumentation Ion Chromatography (IC) Inductively coupled plasma mass spectroscopy (ICP-MS) HPLCs (DAD, UV & RI) UPLC (DAD & UV) RRLC (DAD) GC-HS & GCMSMS LCMSMS Polari meter FTIR Particle Size Analyzer (Sympatec) Differential Scanning Caloriemetry (DSC) Dissolution Tester - Auto Sample

  24. Slide 24: Formulation Development Centre

    ARMA Formulation Developmeni Cenire

  25. Slide 25: Generic/Branded Generic/OTC Product Development

    Generic/Branded Generic/OTC Product Development • Literature Survey • Identification of API Supplier • Patent Review • Quality and Characterization of API • Analytical Development – API • Product Development Strategy Evaluation • Procurement of API / RM / PM / RLD • Lab Scale Development • Analytica

  26. Slide 26: Generic/Branded Generic/OTC Product Development

    Generic/Branded Generic/OTC Product Development • Technology Transfer Verification, Modifications & Adoption • Scale up Batch Production /Modifications (Short Term Stability) • Exhibit Batches Production • Exhibit Batches Stability (Short Term & Long Term) • Pivotal BE Supplies • Compilation of Data

  27. Slide 27: Product Development

    @ SUVEN Product Developmeni

  28. Slide 28: Pre-formulation Studies

    Pre-formulation Studies • Excipient Compatibility Studies • Calorimetry by DSC • Forced-Degradation Studies • Solubility Determination • Bulk Powder Characterization 28

  29. Slide 29: Solid Dosages

    Solid Dosages • Tablets: Immediate Release, Sustained Release, Delayed Release, Chewable, Orally Disintegrating (ODT) and Multilayered • Capsules: Multi-particulates, Powders, Tablet in Capsule, Enteric Coating and Modified Release • Powders: Immediate Release, Sustained Release, Delayed Release, Po

  30. Slide 30: Oral Liquids

    Oral Liquids • Oral solutions, Syrups and Elixirs,… • Oral suspensions • Immediate Release and Powders for Suspensions • Emulsions 30

  31. Slide 31: Topicals

    Topicals • Topical Liquids: Rx, OTC and Personal Care Products for Topical Administration • Topical (Semisolids): Rx, OTC and Personal Care Creams, Gels and Ointments for Topical or Oral Administration (dentifrice) • Ear Drops • Sterile Ophthalmic Preparations • OTIC Products (Solutions & Emulsions)

  32. Slide 32: Injectables

    Injectables • Terminal Sterilization • Filtration • Lyophilization • Powder Filling 32

  33. Slide 33: Process Development Capabilities – R&D

    Process Development Capabilities – R&D • High Shear Mixer Granulation (RMG) • Fluid Bed Granulation (Top Spray) • Roller Compaction & Slugging • Tabletting (Conventional, Bilayer & Tablet in Tablet) • Encapsulation (Powder, Pellet & Tablets or combination thereof) • MUPS (Wurster & Extrusion-Spheron

  34. Slide 34: Packaging Development

    Packaging Development • Blister Packing • Strip Packing • Bottle Packing • Bulk Packing • Liquids Packing • Tube Packing • Pouch Packing 34

  35. Slide 35: List of Equipments – R&D

    List of Equipments – R&D S . No. Description Capacity S . No. Description Capacity 1 Vibro Mechanical Sifter 12 inch 13 Core Coated Tablet Press 20 STN 2 Double Cone Blender 2/5/20 lts Homogeniser (Silent 14 0.8 to 2000 ml Crusher) 3 Rapid Mixer Granulator 3/5/10 lts 500gm -1 kg & 3 kg 15 Autocoater

  36. Slide 36: Regulatory Information

    Regulatory Information (DMF/Product Dossier/Technical Information Submitted) Active Pharmaceutical Intermediates Drug Product / Formulation Ingredients (API) Regulatory Authorities Customer / Country(ies) Customer Customer Suven Suven Suven Specific Specific Specific ANDA ANDA ANADA FDA, USA 16 04 0

  37. Slide 37: Regulatory Inspection History

    Regulatory Inspection History Name of the Regulatory Authority Month & Year April 9 -12, 2007 / November 1 - 4, 2010 February 04 - 08, 2013 / April 04 - 14, 2016 United States Food & Drug Administration (USFDA) February 05 - 15, 2018 October 21 - November 01, 2019 The European Directorate for the Qu

  38. Slide 38: Collaboration - Partnership

    Collaboration - Partnership WE BUILD Customer Focus Speed Transparency Quality Collaboration Integrity & Value Partnership Passion On Time Flexibility 38

  39. Slide 39: Contact Details

    Contact Details K. Jahnavi V. Murali Krishna Prasad, Ph.D. DGM - Business Development AVP – Operations Ph: +91 934-752-4388 Ph: +91 939-248-3017 Email: [email protected] Email: [email protected] Regd. Office: Factory: # 8-2-334, SDE Serene Chambers, Suven Pharmaceuticals Limited, 3rd Floor,

  40. Slide 40: anyveN

    anyveN

Suven Pharmaceuticals — Investor Presentation (2020) on 6ix